Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 4.86
NRCIB's Cash to Debt is ranked higher than
53% of the 174 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.52 vs. NRCIB: 4.86 )
Ranked among companies with meaningful Cash to Debt only.
NRCIB' s 10-Year Cash to Debt Range
Min: 0.05   Max: No Debt
Current: 4.86

Equity to Asset 0.68
NRCIB's Equity to Asset is ranked higher than
61% of the 161 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. NRCIB: 0.68 )
Ranked among companies with meaningful Equity to Asset only.
NRCIB' s 10-Year Equity to Asset Range
Min: 0.51   Max: 0.81
Current: 0.68

0.51
0.81
Interest Coverage 92.77
NRCIB's Interest Coverage is ranked lower than
59% of the 92 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 801.71 vs. NRCIB: 92.77 )
Ranked among companies with meaningful Interest Coverage only.
NRCIB' s 10-Year Interest Coverage Range
Min: 5.98   Max: 9999.99
Current: 92.77

5.98
9999.99
F-Score: 6
Z-Score: 8.73
M-Score: -2.73
WACC vs ROIC
9.23%
28.00%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 25.96
NRCIB's Operating margin (%) is ranked higher than
96% of the 168 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.30 vs. NRCIB: 25.96 )
Ranked among companies with meaningful Operating margin (%) only.
NRCIB' s 10-Year Operating margin (%) Range
Min: 11.54   Max: 30.06
Current: 25.96

11.54
30.06
Net-margin (%) 16.33
NRCIB's Net-margin (%) is ranked higher than
93% of the 168 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.43 vs. NRCIB: 16.33 )
Ranked among companies with meaningful Net-margin (%) only.
NRCIB' s 10-Year Net-margin (%) Range
Min: 2.82   Max: 19.63
Current: 16.33

2.82
19.63
ROE (%) 19.21
NRCIB's ROE (%) is ranked higher than
89% of the 162 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.60 vs. NRCIB: 19.21 )
Ranked among companies with meaningful ROE (%) only.
NRCIB' s 10-Year ROE (%) Range
Min: 2.82   Max: 31.68
Current: 19.21

2.82
31.68
ROA (%) 12.98
NRCIB's ROA (%) is ranked higher than
94% of the 175 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.19 vs. NRCIB: 12.98 )
Ranked among companies with meaningful ROA (%) only.
NRCIB' s 10-Year ROA (%) Range
Min: 2.05   Max: 22.3
Current: 12.98

2.05
22.3
ROC (Joel Greenblatt) (%) 215.83
NRCIB's ROC (Joel Greenblatt) (%) is ranked higher than
98% of the 174 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.66 vs. NRCIB: 215.83 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NRCIB' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 20.77   Max: 235.4
Current: 215.83

20.77
235.4
Revenue Growth (3Y)(%) -43.40
NRCIB's Revenue Growth (3Y)(%) is ranked lower than
90% of the 114 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.60 vs. NRCIB: -43.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NRCIB' s 10-Year Revenue Growth (3Y)(%) Range
Min: -43.4   Max: 19.7
Current: -43.4

-43.4
19.7
EBITDA Growth (3Y)(%) -42.70
NRCIB's EBITDA Growth (3Y)(%) is ranked lower than
89% of the 101 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.30 vs. NRCIB: -42.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NRCIB' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -42.7   Max: 42
Current: -42.7

-42.7
42
EPS Growth (3Y)(%) -39.70
NRCIB's EPS Growth (3Y)(%) is ranked lower than
83% of the 96 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.80 vs. NRCIB: -39.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NRCIB' s 10-Year EPS Growth (3Y)(%) Range
Min: -39.7   Max: 58.7
Current: -39.7

-39.7
58.7
» NRCIB's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

NRCIB Guru Trades in Q2 2014

Chuck Royce 2,100 sh (unchged)
» More
Q3 2014

NRCIB Guru Trades in Q3 2014

Chuck Royce 2,100 sh (unchged)
» More
Q4 2014

NRCIB Guru Trades in Q4 2014

Chuck Royce 1,780 sh (-15.24%)
» More
Q1 2015

NRCIB Guru Trades in Q1 2015

Chuck Royce Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with NRCIB

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on National Research Corp

Meridian Funds Comments on National Research Corp - Jun 20, 2014

National Research Corp. (NRCIB) experienced strong gains during the two-week period ending December 31, 2013. The company provides performance measurement services to the healthcare industry to help providers and payers measure outcomes. We believe that National Research is well positioned for the evolving healthcare landscape and has a strong business model characterized by recurring revenues, high margins, and returns on equity in excess of 20%. Additionally, the A shares owned by the Fund closed the year at a 45.8% discount to the B shares; we expect this valuation discrepancy to narrow over time.



From Meridian Funds's semi-annual report ended December 31, 2013.



Check out Meridian Funds latest stock trades

Top Ranked Articles about National Research Corp

Meridian Funds Comments on National Research Corp
National Research Corp. (NRCIB) experienced strong gains during the two-week period ending December 31, 2013. The company provides performance measurement services to the healthcare industry to help providers and payers measure outcomes. We believe that National Research is well positioned for the evolving healthcare landscape and has a strong business model characterized by recurring revenues, high margins, and returns on equity in excess of 20%. Additionally, the A shares owned by the Fund closed the year at a 45.8% discount to the B shares; we expect this valuation discrepancy to narrow over time. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 50.00
NRCIB's P/E(ttm) is ranked lower than
99% of the 76 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 27.40 vs. NRCIB: 50.00 )
Ranked among companies with meaningful P/E(ttm) only.
NRCIB' s 10-Year P/E(ttm) Range
Min: 2.18   Max: 68.23
Current: 50

2.18
68.23
Forward P/E 11.16
NRCIB's Forward P/E is ranked higher than
90% of the 62 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.34 vs. NRCIB: 11.16 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 50.80
NRCIB's PE(NRI) is ranked lower than
73% of the 79 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 33.80 vs. NRCIB: 50.80 )
Ranked among companies with meaningful PE(NRI) only.
NRCIB' s 10-Year PE(NRI) Range
Min: 2.18   Max: 68.45
Current: 50.8

2.18
68.45
P/B 9.00
NRCIB's P/B is ranked lower than
137% of the 142 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.60 vs. NRCIB: 9.00 )
Ranked among companies with meaningful P/B only.
NRCIB' s 10-Year P/B Range
Min: 0.4   Max: 16.26
Current: 9

0.4
16.26
P/S 8.10
NRCIB's P/S is ranked lower than
124% of the 147 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.90 vs. NRCIB: 8.10 )
Ranked among companies with meaningful P/S only.
NRCIB' s 10-Year P/S Range
Min: 0.32   Max: 11.58
Current: 8.1

0.32
11.58
PFCF 40.50
NRCIB's PFCF is ranked lower than
118% of the 62 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 22.50 vs. NRCIB: 40.50 )
Ranked among companies with meaningful PFCF only.
NRCIB' s 10-Year PFCF Range
Min: 1.45   Max: 68.45
Current: 40.5

1.45
68.45
POCF 36.41
NRCIB's POCF is ranked lower than
78% of the 80 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.74 vs. NRCIB: 36.41 )
Ranked among companies with meaningful POCF only.
NRCIB' s 10-Year POCF Range
Min: 1.23   Max: 58.94
Current: 36.41

1.23
58.94
EV-to-EBIT 15.27
NRCIB's EV-to-EBIT is ranked higher than
73% of the 91 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 22.34 vs. NRCIB: 15.27 )
Ranked among companies with meaningful EV-to-EBIT only.
NRCIB' s 10-Year EV-to-EBIT Range
Min: -0.2   Max: 43.2
Current: 15.27

-0.2
43.2
Shiller P/E 17.40
NRCIB's Shiller P/E is ranked higher than
87% of the 55 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. NRCIB: 17.40 )
Ranked among companies with meaningful Shiller P/E only.
NRCIB' s 10-Year Shiller P/E Range
Min: 2.84   Max: 19.73
Current: 17.4

2.84
19.73
Current Ratio 1.93
NRCIB's Current Ratio is ranked lower than
66% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.64 vs. NRCIB: 1.93 )
Ranked among companies with meaningful Current Ratio only.
NRCIB' s 10-Year Current Ratio Range
Min: 0.49   Max: 5.41
Current: 1.93

0.49
5.41
Quick Ratio 1.93
NRCIB's Quick Ratio is ranked lower than
59% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.30 vs. NRCIB: 1.93 )
Ranked among companies with meaningful Quick Ratio only.
NRCIB' s 10-Year Quick Ratio Range
Min: 0.49   Max: 5.41
Current: 1.93

0.49
5.41
Days Sales Outstanding 43.49
NRCIB's Days Sales Outstanding is ranked higher than
77% of the 150 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 64.52 vs. NRCIB: 43.49 )
Ranked among companies with meaningful Days Sales Outstanding only.
NRCIB' s 10-Year Days Sales Outstanding Range
Min: 29.97   Max: 82.49
Current: 43.49

29.97
82.49

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.20
NRCIB's Dividend Yield is ranked higher than
60% of the 50 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. NRCIB: 2.20 )
Ranked among companies with meaningful Dividend Yield only.
NRCIB' s 10-Year Dividend Yield Range
Min: 0.94   Max: 23.2
Current: 2.2

0.94
23.2
Dividend Payout 1.09
NRCIB's Dividend Payout is ranked higher than
78% of the 41 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.27 vs. NRCIB: 1.09 )
Ranked among companies with meaningful Dividend Payout only.
NRCIB' s 10-Year Dividend Payout Range
Min: 0.28   Max: 3.47
Current: 1.09

0.28
3.47
Dividend growth (3y) -41.10
NRCIB's Dividend growth (3y) is ranked lower than
86% of the 21 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 7.70 vs. NRCIB: -41.10 )
Ranked among companies with meaningful Dividend growth (3y) only.
NRCIB' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 20.5
Current: -41.1

0
20.5
Yield on cost (5-Year) 0.62
NRCIB's Yield on cost (5-Year) is ranked lower than
142% of the 52 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.75 vs. NRCIB: 0.62 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
NRCIB' s 10-Year Yield on cost (5-Year) Range
Min: 0.26   Max: 6.53
Current: 0.62

0.26
6.53
Share Buyback Rate -93.00
NRCIB's Share Buyback Rate is ranked lower than
94% of the 104 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.50 vs. NRCIB: -93.00 )
Ranked among companies with meaningful Share Buyback Rate only.
NRCIB' s 10-Year Share Buyback Rate Range
Min: 7   Max: -94.1
Current: -93

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 157.90
NRCIB's Price/Net Current Asset Value is ranked lower than
152% of the 83 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. NRCIB: 157.90 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
NRCIB' s 10-Year Price/Net Current Asset Value Range
Min: 0.33   Max: 313.43
Current: 157.9

0.33
313.43
Price/Tangible Book 33.20
NRCIB's Price/Tangible Book is ranked lower than
140% of the 138 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.80 vs. NRCIB: 33.20 )
Ranked among companies with meaningful Price/Tangible Book only.
NRCIB' s 10-Year Price/Tangible Book Range
Min: 0.2   Max: 3494
Current: 33.2

0.2
3494
Price/DCF (Projected) 3.70
NRCIB's Price/DCF (Projected) is ranked lower than
113% of the 67 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.60 vs. NRCIB: 3.70 )
Ranked among companies with meaningful Price/DCF (Projected) only.
NRCIB' s 10-Year Price/DCF (Projected) Range
Min: 0.12   Max: 5.34
Current: 3.7

0.12
5.34
Price/Median PS Value 14.90
NRCIB's Price/Median PS Value is ranked lower than
140% of the 146 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.00 vs. NRCIB: 14.90 )
Ranked among companies with meaningful Price/Median PS Value only.
NRCIB' s 10-Year Price/Median PS Value Range
Min: 0.2   Max: 21
Current: 14.9

0.2
21
Price/Graham Number 8.60
NRCIB's Price/Graham Number is ranked lower than
128% of the 69 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.20 vs. NRCIB: 8.60 )
Ranked among companies with meaningful Price/Graham Number only.
NRCIB' s 10-Year Price/Graham Number Range
Min: 0.12   Max: 81.26
Current: 8.6

0.12
81.26
Earnings Yield (Greenblatt) 6.60
NRCIB's Earnings Yield (Greenblatt) is ranked higher than
87% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.20 vs. NRCIB: 6.60 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
NRCIB' s 10-Year Earnings Yield (Greenblatt) Range
Min: 2.3   Max: 2139.6
Current: 6.6

2.3
2139.6
Forward Rate of Return (Yacktman) -31.62
NRCIB's Forward Rate of Return (Yacktman) is ranked lower than
100% of the 55 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 11.51 vs. NRCIB: -31.62 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) only.
NRCIB' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -31.9   Max: 65.8
Current: -31.62

-31.9
65.8

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:ADP, G, ENV, CMPGY, SGSOY » details
National Research Corp is a Wisconsin corporation, founded in 1981. The Company implements surveys and performs analysis that recognize a provider's strengths and problem areas, and then uses the data to design specific, measurable improvement strategies. The Company's portfolio of subscription-based solutions provide actionable information and analysis to healthcare organizations and payers across a range of mission-critical, constituent-related elements, including patient experience and satisfaction, community population health risks, workforce engagement, community perceptions, and physician engagement. The Company partners with clients across the continuum of healthcare services. The Company's clients range from acute care hospitals and post-acute providers, such as home health, long term care and hospice, to numerous payer organizations. The two operating segments, organized by geographic area, are National Research Corporation (United States) and National Research Corporation Canada, which each offer a portfolio of solutions to address specific market needs around growth, retention, engagement and thought leadership for healthcare organizations. The Company's primary competitors among such specialty firms include Press Ganey. The Company competes with traditional market research firms which are significant providers of survey-based, general market research and firms which provide services or products that complement healthcare performance assessments such as healthcare software or information systems.
» More Articles for NRCIB

Headlines

Articles On GuruFocus.com
Meridian Funds Comments on National Research Corp Jun 20 2014 
My 4 Favorite Stocks From The Undervalued Predictable Screener Oct 11 2013 
Four Predictable, Undervalued Stocks Held by Billionaire Investors Sep 22 2013 
13 Not Expensive Stocks with Dividend Yields Over 3% as Well as a Consistent Business Sep 10 2013 
4 Really Undervalued Stocks With High Quality Dividends And A Consistent Business Sep 02 2013 

More From Other Websites
10-Q for National Research Corp. May 11 2015
National Research Corporation Announces First Quarter 2015 Results May 08 2015
National Research Corporation Announces First Quarter 2015 Results May 07 2015
Q1 2015 National Research Corp Earnings Release - After Market Close May 07 2015
National Research Corporation Canada Becomes First Approved to Field Canadian Patient Experiences... Apr 30 2015
Nasdaq stocks posting largest volume increases Apr 29 2015
National Research Corporation Canada Becomes First Approved to Field Canadian Patient Experiences... Apr 29 2015
National Research Corporation to Broadcast Its 2015 First Quarter Conference Call Live on the... Apr 29 2015
ARTICLE: PRACTICAL APPROACHES TO CARE TRANSITIONS STRATEGIES FROM HOSPITAL TO HOME HEALTH Apr 28 2015
Report: Georgia Nursing Homes Exceed National Satisfaction Rates Apr 24 2015
REPORT: GEORGIA NURSING HOMES EXCEED NATIONAL SATISFACTION RATES Apr 24 2015
Nielsen Holdings (NLSN) Misses Q1 Earnings and Revenues - Analyst Blog Apr 22 2015
NATIONAL RESEARCH CORPORATION AND VISITING NURSE ASSOCIATIONS OF AMERICA TO ENCOURAGE VNAA MEMBERS... Apr 20 2015
National Research Corporation and Visiting Nurse Associations of America to encourage VNAA members... Apr 20 2015
Alabama Nursing Homes Continue to Exceed National Satisfaction Rates; Alabama Nursing Home... Apr 16 2015
Alabama Nursing Homes Continue to Exceed National Satisfaction Rates; Alabama Nursing Home... Apr 16 2015
National Research Reaches 25,000-Physician Milestone with Healthcare Transparency Solution Apr 09 2015
National Research Reaches 25,000-Physician Milestone with Healthcare Transparency Solution Apr 09 2015
National Research Corporation Declares Quarterly Dividend Mar 09 2015
GOVERNANCE TRAINING PROGRAM IN QUALITY AND SAFETY COMING SOON Mar 09 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK